drugset
drugset / Trial / NCT01158274

RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors

NCT01158274 ↗

Phase 1 Completed 30 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I clinical trial is studying the side effects and best dose of RO4929097 when given together with capecitabine in treating patients with refractory solid tumors. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving RO4929097 together with chemotherapy may kill more tumor cells.

Timeline

Start
2010-06
Primary completion
2012-08
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule — Oral
Subject RG4733 Small molecule — Oral

Indications

AIDS-related primary central nervous system lymphoma Burkitt lymphoma Her2-receptor negative breast cancer Hodgkins lymphoma MALT lymphoma Waldenstrom macroglobulinemia adult T-cell leukemia/lymphoma anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma cancer of unknown primary site central nervous system non-hodgkin lymphoma chronic lymphocytic leukemia/small lymphocytic lymphoma extranodal nasal NK/T cell lymphoma female breast carcinoma grade III lymphomatoid granulomatosis immunodeficiency-associated lymphoproliferative disease intraocular lymphoma large-cell immunoblastic lymphoma male breast carcinoma malignant colon neoplasm mantle cell lymphoma mycosis fungoides and variants nodal marginal zone B-cell lymphoma post-transplant lymphoproliferative disease primary cutaneous B-cell lymphoma primary cutaneous T-cell non-Hodgkin lymphoma rectal carcinoma small intestine lymphoma splenic marginal zone lymphoma